Seminars in Oncology
Volume 30, Issue 2 , Pages 156-160 , April 2003

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias

References 

  1. Golub TR, Slonim DK, Tamayo P, et al.  Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537
  2. Petricoin EF, Ardekani AM, Hitt BA, et al.  Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–577
  3. Petricoin EF, Ornstein DK, Paweletz CP, et al.  Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94:1576–1578
  4. Sreekumar A, Nyati MK, Varambally S, et al.  Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteins. Cancer Res. 2001;61:7585–7593
  5. Mitsiades CS, Mitsiades N, Poulaki V, et al.  The hsp90 molecular chaperone as a novel therapeutic target in hematologic malignancies. Blood. 2001;11S(suppl 1):377a; abstr)
  6. Mitsiades CS, Mitsiades N, Poulaki V, et al.  High-throughput global proteomic analysis of the signaling state of human multiple myeloma cells. Blood. 2001;98(suppl 1):3058a; abstr)
  7. Mitsiades CS, Mitsiades N, Poulaki V, et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene. 2002;21:5673–5683
  8. Mitsiades N, Mitsiades CS, Poulaki V, et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. Blood. 2002;99:4525–4530
  9. Mitsiades N, Mitsiades CS, Poulaki V, et al.  Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood. 2002;99:4079–4086
  10. Mitsiades N, Mitsiades CS, Poulaki V, et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374–14379
  11. Zhang L, Pelech SL, Mayrand D, et al.  Bacterial heat shock protein-60 increases epithelial cell proliferation through the ERK1/2 MAP kinases. Exp Cell Res. 2001;266:11–20
  12. Zhang H, Shi X, Hampong M, et al.  Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem. 2001;276:6905–6908
  13. Zhang H, Shi X, Zhang QJ, et al.  Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT-116 cells. J Biol Chem. 2002;46:43648–43658
  14. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents. Blood (in press)
  15. Al-Katib A, Mohammad R, Hamdan M, et al.  Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: Utility as a preclinical drug screening model. Blood. 1993;81:3034–3042
  16. Mitsiades CS, Mitsiades N, Richardson PG, et al.  Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:309–312

☆ Supported by the International Waldenstrom's Macroglobulinemia Foundation (C.S.M), Multiple Myeloma Research Foundation (C.S.M and N.M.), Lauri Strauss Leukemia Foundation (C.S.M), and by a Doris Duke Distinguished Clinical Scientist Award (K.C.A).

☆☆ Address reprint requests to Kenneth C. Anderson, MD, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Mayer Building, Room M555, Boston, MA 02115.

★ 0093-7754/03/3002-3031$30.00/0

PII: S0093-7754(03)70068-2

doi: 10.1053/sonc.2003.50066

Seminars in Oncology
Volume 30, Issue 2 , Pages 156-160 , April 2003

Article Tools

* Image Usage & Resolution